Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pan-HER inhibitor FCN-411

An orally bioavailable pan-human epidermal growth factor receptors (EGFR; HER) tyrosine kinase inhibitor, with potential antineoplastic activity. Upon oral administration, pan-HER inhibitor FCN-411 targets, binds to and inhibits human epidermal growth factor receptors (HER) EGFR (HER1; ErbB1), HER2 (neu, ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4), and including EGFR activating and resistance mutations such as EGFR T790M/L858. This inhibits downstream signaling leading to the inhibition of proliferation of tumor cells that overexpress these receptors. EGFR family members play key roles in regulating cell proliferation and differentiation, and are overexpressed in many different tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:FCN 411
FCN-411
FCN411
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search